---
title: "Analyst Reiterates Buy on MBX, Maintains $91 Price Target on Canvuparade’s Once-Weekly Hypoparathyroidism Opportunity"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290237349.md"
description: "LifeSci Capital analyst Patrick Dolezal reiterated a Buy rating on MBX Biosciences with a $91 price target, citing canvuparade's once-weekly dosing advantage over competitor Yorvipath and a large underpenetrated patient pool. Barclays also maintained a Buy rating with a $70 target."
datetime: "2026-06-18T19:05:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290237349.md)
  - [en](https://longbridge.com/en/news/290237349.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290237349.md)
generator: "portal-rs"
---

# Analyst Reiterates Buy on MBX, Maintains $91 Price Target on Canvuparade’s Once-Weekly Hypoparathyroidism Opportunity

Patrick Dolezal, an analyst from LifeSci Capital, maintained the Buy rating on MBX Biosciences, Inc.. The associated price target remains the same with $91.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Patrick Dolezal has given his Buy rating due to a combination of factors tied to MBX’s lead program, canvuparade, and its positioning in the hypoparathyroidism market. He views the once‑weekly profile as a meaningful convenience upgrade over the once‑daily standard Yorvipath, with AVAIL Phase 2 data suggesting efficacy broadly in line with the approved competitor, which should be acceptable given the dosing advantage.

He also highlights that physician feedback points to a sizeable, underpenetrated patient pool for PTH replacement, implying a large addressable opportunity as Yorvipath’s current sales may reflect only a fraction of demand. In his view, upcoming Phase 3 optimization—such as autoinjector use, a standardized starting dose, and a more comparable patient mix—could enhance canvuparade’s risk‑benefit profile, supporting the investment case and justifying maintaining a $91 price target while reiterating a Buy rating on MBX.

In another report released on June 15, Barclays also maintained a Buy rating on the stock with a $70.00 price target.

### Related Stocks

- [MBX.US](https://longbridge.com/en/quote/MBX.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)

## Related News & Research

- [Bank of New York Mellon Corp Purchases Shares of 88,927 MBX Biosciences, Inc. $MBX](https://longbridge.com/en/news/298099359.md)
- [Analyst Maintains Buy on Microbix as China Antigen Sales Normalize and Revenue Growth Recovers](https://longbridge.com/en/news/296018935.md)
- [Analyst Shrenik Kothari Reiterates Buy on GitLab as Strong Execution, Upgraded Guidance and Recovering Demand Signal Further Upside](https://longbridge.com/en/news/297731371.md)
- [RBC Capital Keeps Their Buy Rating on Cytokinetics (CYTK)](https://longbridge.com/en/news/297724700.md)
- [DBS Reaffirms Their Buy Rating on NIO Inc. Class A (9866)](https://longbridge.com/en/news/297745393.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**